First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
The company will be the first to take a FcRH5-targeting project into phase 3.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.